Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673452 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 530
- Enrollment target
NCT00673452 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 530 participants.
The verdict
NCT00673452, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 530 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older. Patients will be randomized to duloxetine or placebo, however, all patients will receive duloxetine at some point in the study.
Interventions
- DRUG placebo
- DRUG duloxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673452
The ClinicalTrials.gov registry entry for NCT00673452 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00673452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673452 about?
NCT00673452 is a clinical study titled "A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia". The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older. Patients will be randomized to duloxetine or placebo, however, all patients will receive...
What is the current status of trial NCT00673452?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 530 participants. The study started on 2008-06. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00673452?
The interventions under investigation include: placebo (DRUG), duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00673452?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.